Regenxbio Inc Interim Data Update Transcript
Good day, and thank you for standing by. Welcome to REGENXBIO's data update from Phase II ALTITUDE trial of ABBV-RGX-314 for the treatment of diabetic retinopathy using suprachoroidal delivery from AAO 2023.Ã (Operator Instructions) After the speakers' presentation, there will be a question-and-answer session. (Operator Instructions)
Please be advised today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Ken Mills, Chief Executive Officer. Please go ahead.
Welcome, everyone, to our American Academy of Ophthalmology or AAO event update. I'm Ken Mills, CEO of REGENXBIO, and I'm pleased to introduce our agenda and make some opening remarks. This event is designed to review and discuss the new interim data from our ALTITUDE clinical trial ofà ABBV-RGX-314,à henceforthà referred to as 314 for diabetic retinopathy or DR using one-time in-office suprachoroidal delivery. The slides for this presentation are available on the webcast and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |